Adapting Pharmaceutical Commercialization Models

This document is a report discussing the evolving landscape of pharmaceutical commercialization in response to significant revenue declines faced by the industry. It outlines the challenges manufacturers encounter, including patent cliffs, rising patient acquisition costs, convoluted supply chain management, fragmented execution, lack of pricing transparency, and complicated relationships with pharmacy benefit managers (PBMs). The report explains that traditional commercialization strategies are no longer effective, necessitating a shift towards more flexible and sustainable approaches. It introduces the Direct-to-Patient (DTP) model, EVERSANA DIRECT Commercialization™, as a solution that streamlines access to patient care and improves engagement. The DTP model is presented as a comprehensive approach that integrates various services to enhance patient adherence and reduce costs. The report emphasizes the importance of adapting to the new pharmaceutical landscape to maintain competitiveness and profitability.